What Desyrel Treats: Main Uses and Benefits

The medication is commonly used across therapeutic domains where additional symptomatic support is needed to manage persistent mood and sleep disturbances. It is applied in clinical settings that involve acute or unstable symptom patterns, such as those seen in Major Depressive Disorder, specifically in addressing the symptoms of low mood, sadness, and loss of interest that interfere with daily functioning.

This treatment is relevant in conditions characterized by periods of heightened symptoms, specifically the affective burden of unipolar depression, and is commonly used to help with symptom clusters that may become intense or disruptive, such as insomnia and states of hyper-arousal. It is also applied in complex clinical settings where supportive symptom management is appropriate, including providing relief for disruptive behavioral symptoms in older adults and contributing to symptomatic support for certain chronic pain syndromes.

“The primary goal is easing the overall symptom load and helping patients cope more steadily with difficult episodes.”

The medication is considered relevant for managing symptoms that interfere with daily comfort, and may assist with maintaining a sense of stability when symptoms are more noticeable, assisting with sleep initiation and providing a commonly used calming effect.

---

Quick Fact: Relief for Sleep and Mood

Symptom Axis	Key Symptoms Relieved	Therapeutic Benefit
Mood	Low mood, loss of interest, affective distress	Plays a role in managing symptoms related to emotional state.
Sleep	Insomnia, nighttime awakenings, restlessness	Contributes to improved comfort during symptomatic periods.

Regulatory References

1. NIH MedlinePlus Drug Information

Official Eligibility and Restriction Profile

Official regulatory documents define the eligible patient population for Desyrel (Trazodone) based on age, current medication use, and specific health conditions.

Population Eligibility Status	Official Regulatory Statement
Approved Population	Adults (18 years of age and older). Approved for treating Major Depressive Disorder.
Absolute Contraindications	Patients with known hypersensitivity to the drug or those who have recently used (within 14 days) a Monoamine Oxidase Inhibitor (MAOI).
Use Not Recommended	Patients in the initial recovery phase following a myocardial infarction (heart attack).

Age-Related Constraints

• Pediatric Patients (< 18 years): Use is not approved as safety and efficacy have not been established in this age group.
• Geriatric Patients (Older Adults): Use requires caution due to increased risks such as orthostatic hypotension and hyponatremia (low sodium levels).

Conditional Use and Restrictions

Patients with certain co-morbidities require careful consideration based on regulatory warnings:

• Cardiac Disease: Use with caution and monitoring due to the potential for arrhythmias and QTc interval prolongation.
• Organ Impairment: Caution is advised in patients with renal or hepatic impairment, as official studies establishing safety in these specific populations are insufficient.
• Other Risks: Caution is advised in men with conditions predisposing to priapism and in patients with untreated anatomically narrow angles (glaucoma risk).

Interactions with other medicines and products

Desyrel (trazodone) interacts with several medication classes and substances, primarily due to its metabolic pathway and pharmacologic effects on the central nervous system. These interactions are summarized in official prescribing information.

---

Contraindicated and High-Risk Combinations

• Monoamine Oxidase Inhibitors (MAOIs): Trazodone is strictly contraindicated for use concurrently with or within 14 days of discontinuing an MAOI. This restriction is due to the significant risk of developing Serotonin Syndrome.
• Serotonergic Agents: Combining Desyrel with other serotonergic drugs (e.g., SSRIs, SNRIs, triptans, Lithium) increases the risk of Serotonin Syndrome.

---

Pharmacokinetic and Exposure Modification

Interacting Agent Type	Effect on Trazodone Levels	Required Constraint
Strong CYP3A4 Inhibitors (e.g., Ritonavir, Ketoconazole)	Increases plasma concentrations	Dose reduction of Trazodone may be needed
Strong CYP3A4 Inducers (e.g., Carbamazepine, Rifampin)	Decreases plasma concentrations	Dose increase of Trazodone may be needed

---

Other Pharmacodynamic Interactions

• CNS Depressants: The sedative effects of alcohol, barbiturates, and other CNS depressants may be enhanced by trazodone.
• Antiplatelet Agents and Anticoagulants: Co-administration with drugs like Warfarin, Aspirin, or NSAIDs is associated with an increased risk of bleeding.
• QTc Prolonging Drugs: Avoid combining Desyrel with other medications that prolong the QTc interval due to the increased risk of cardiac arrhythmias.

How Desyrel Works

Desyrel (Trazodone) functions through multiple pharmacodynamic actions primarily in the central nervous system. The compound's core mechanism is high-affinity antagonism of the serotonin 5- HT2A receptor. This binding prevents the endogenous ligand from activating the receptor, thereby modulating its intracellular signaling pathway .

Additionally, Desyrel acts as a weak inhibitor of the serotonin transporter (SERT). Inhibition of SERT blocks the reuptake of serotonin from the synaptic cleft, resulting in an increased concentration and extended residence time of the neurotransmitter in the synapse. Trazodone also exhibits antagonism at both alpha1-adrenergic and histamine H1 receptors. The cumulative effect of these defined molecular interactions is a broad neuromodulatory action influencing multiple signaling cascades.

Desyrel (Trazodone Hydrochloride) is administered solely by the oral route and is available in Immediate-Release (IR) and Extended-Release (ER) tablet formulations. Usage is based on standard dosage and administration instructions.

Official Dosing and Administration

Administration Parameter	Immediate-Release (IR) Tablets	Extended-Release (ER) Tablets
Starting Dose (Adults)	150 mg/day in divided doses.	150 mg once daily.
Dose Adjustment	Increase by 50 mg/day every 3 to 4 days.	Increase by 75 mg/day every 3 days.
Maximum Dose (Outpatient)	Up to 400 mg/day in divided doses.	Up to 375 mg/day.

Administration Instructions

Standard instructions detail parameters for intake:

• IR Tablets should be taken shortly after a meal or light snack. This instruction is provided to enhance patient tolerability. The total daily dose is typically divided, with the largest portion often taken at bedtime.
• ER Tablets must be taken on an empty stomach, generally in the late evening.
• Tablets can be swallowed whole or, if scored, broken in half. They must not be crushed or chewed.

Population-Specific Instructions

• Older Adults: The recommended initial starting dose may be reduced to 100 mg/day (in divided doses or a single night-time dose) for the very elderly or frail, and the total dose is unlikely to exceed 300 mg/day.
• Pediatric Population: Trazodone is not recommended for children below 18 years due to insufficient safety and efficacy data.

Upon achieving an adequate response, the dosage should be gradually reduced rather than abruptly discontinued.

Research evidence / Overview of studies for Desyrel

---

Evidence Base for Major Depressive Disorder (MDD)

The most robust body of research involves Trazodone being studied for Major Depressive Disorder (MDD). Research in this area primarily consists of Randomized Controlled Trials (RCTs), alongside detailed systematic reviews and meta-analyses. These studies monitored physiological strain or stress and often compared Trazodone with a placebo or with other active antidepressant medications.

Acute Treatment Trials and Measured Outcomes

The clinical research in MDD has focused extensively on the acute treatment period, which typically involves studies lasting between 6 and 12 weeks. Study outcomes examined changes in symptom intensity or variability using standardized tools, such as the Hamilton Depression Rating Scale (HAM-D) and the Montgomery–Åsberg Depression Rating Scale (MADRS). Studies reported measurements of symptom change on these scales. However, while research provides insight into short-term changes, the mean difference in effect size when compared to placebo in meta-analyses has sometimes been described as modest.

---

Evidence Base for Sleep Disturbances and Insomnia

Desyrel was also evaluated in research exploring how symptoms change over time for individuals experiencing sleep disturbances. Studies monitored physiological strain or stress, including using objective measures like Polysomnography (PSG), alongside patient-reported outcomes describing perceived discomfort. The findings related to sleep often show that studies reported patterns related to change in patient-reported outcomes, such as the number of nighttime awakenings and overall perceived sleep quality.

However, findings were inconsistent when it came to objective measurements of sleep efficiency and total sleep time derived from PSG studies. Evidence remains limited and heterogeneous, with some official sources citing concerns about the small sample sizes in many key studies.

---

Studies of Specific Symptoms: Anxiety and Agitation

Research has explored how specific mood symptoms were measured and changed in the observed populations, such as anxiety and psychomotor agitation. Findings for this domain often come from analyzing secondary outcomes within the larger MDD clinical trials. Studies often observed that patterns of change in anxiety and agitation scores were measured within a rapid time frame, compared to the longer time intervals needed for changes in core mood symptoms. However, findings for these symptoms are often considered indirect, as few large-scale clinical trials have used anxiety or agitation as the primary focus of study, and data are still emerging.

---

Long-Term Evidence and Durability of Effect

Clinical research provides greater context for short-term outcomes (up to a few months) than for the sustained use of Trazodone. However, the long-term effects are not fully established through extensive randomized trials. While research contributes to understanding symptom patterns, there is limited information available for long-term outcomes, particularly concerning the durability of any symptomatic management and the prevention of symptoms from returning over many months or years.

---

Evidence in Special Populations

Trazodone was studied in specific patient groups. Older adults (geriatric populations) with MDD have been included in research examining patient-reported experiences. These studies report how symptoms evolved in the observed populations during periods where symptoms become more noticeable. However, for other specific groups, research is ongoing and data remain insufficient. For example, evidence for use in children and adolescents is limited, and available findings were often mixed.

---

Evidence Gaps and Research Uncertainty

While research contributes to the broader evidence landscape, there are still areas where certainty remains low or where more studies are needed. One key limitation is that sample sizes were modest in some of the more specialized trials, particularly those focused only on sleep. Furthermore, long-term effects are not fully established, as follow-up durations were limited in many acute treatment RCTs. There is also limited information for its use as a stand-alone treatment for pure anxiety disorders, as evidence often stems from its observed use as an adjunctive benefit in depression trials.

Key Studies & References

1. Trazodone Efficacy in Depression (TED): A Naturalistic Study on the Efficacy of Trazodone in an Extended-Release Formulation Compared to SSRIs (MDPI, 2023)
2. A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder (Current Medical Research and Opinion, 2020)

Common questions about Desyrel (FAQ)

---

Q: Can Desyrel cause weight gain or weight loss?

Regulatory documents state that changes in weight, meaning either weight gain or weight loss, have been reported as a common side effect of Desyrel. It is important to know that these changes are listed as potential effects in the official product information.

---

Q: How long does Desyrel stay in your system?

According to official product information, Desyrel (trazodone) has a relatively short half-life, which is the time it takes for half the drug to be eliminated from the body. Studies indicate its elimination half-life is approximately 3 to 6 hours for the initial phase, and 5 to 9 hours for the second, slower phase. Regulatory documents describe this pharmacokinetic profile in the context of the drug's approved dosing schedules.

---

Q: Can Desyrel cause suicidal thoughts?

Official information indicates that Desyrel may increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (under 25 years old). This is a known warning for antidepressant medicines. The official warning notes that this risk is generally observed at the start of therapy or following changes in dosage.

---

Q: Is Desyrel a controlled substance?

The official product information clarifies that Desyrel (trazodone) is not currently classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA). This means it does not fall under the federal schedules for drugs that have a high potential for abuse.

---

Q: Can Desyrel affect sexual function?

According to official sources, sexual side effects have been reported with the use of Desyrel. Specific issues mentioned include priapism—a prolonged, painful erection that is considered a medical emergency and should be addressed promptly—as well as decreased libido (sex drive) and impotence (erectile dysfunction).

---

Q: Can Desyrel be used for sleep?

Official information indicates that Desyrel is approved for the treatment of depression. Due to its sedating effects, regulatory documents note it has been used in clinical practice for sleep difficulties, though this is considered an off-label use. The official product label describes Desyrel's approved use as an antidepressant.

---

Q: Can Desyrel affect your blood pressure?

Regulatory documents state that Desyrel can cause orthostatic hypotension, which is a drop in blood pressure when moving from sitting or lying down to standing. This can potentially lead to dizziness or fainting. Changes in blood pressure are a recognized side effect in the official product information.

---

Q: Does Desyrel cause addiction or dependence?

According to official product information, Desyrel does not carry a high risk of addiction or physical dependence in the same way as some other classes of medication. However, stopping the drug abruptly, especially after prolonged use, may lead to discontinuation symptoms, which is a sign of physical adaptation to the drug.

Desyrel (Trazodone) tablets should be stored at room temperature, generally between 68 F to 77 F (20 C to 25 C). Keep the medication in the original container, tightly closed, and keep it away from excessive heat, moisture, and direct light. Do not store it in the bathroom, and protect it from freezing.

It is crucial to keep this and all medications out of the sight and reach of children and pets.

To dispose of unused or expired Desyrel, you should not flush it down a toilet or pour it down a sink unless instructed otherwise by a healthcare professional. The preferred method for disposal is through a drug take-back program. Consult your pharmacist or local waste disposal service for available take-back opportunities in your community. If a take-back option is not available, you may dispose of the medicine in the household trash by mixing it with an undesirable substance like used coffee grounds or cat litter, placing the mixture in a sealed bag or container, and discarding it.